Inhaled Budesonide in the Treatment of Early COVID 19 STOIC A phase 2 Open label Randomised Controlled Trial access Lancet Respir Med article

Submitted by vgreene on Fri, 09/24/2021 - 12:30
Detail (Long)
Inhaled Budesonide in the Treatment of Early COVID-19 (STOIC): A phase 2, Open-label, Randomised Controlled Trial; <a href=https://www.thelancet.com/article/S2213-2600(21)00160-0/fulltext><b><u>access <i>Lancet Respir Med</i> article</u></b></a>